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and Related Diseases 2014We are pleased to announce that Allergology International (AI)
is publishing the proceedings of the 28thWorkshop on Eosinophils
in Allergy and Related Diseases. This Workshop was ﬁrst estab-
lished by Prof. Sohei Makino of Dokkyo University in 1988 and
has since been held annually under the strong leadership of Prof.
Makino, Prof. Takeshi Fukudadalso of Dokkyo Universitydand
Prof. Makoto Nagata of Saitama Medical University.
The 2014Workshopwas held in Tokyo on October 4, 2014. It was
supervised by me (K. Matsumoto; National Research Institute for
Child Health and Development) and comprised 28 oral presenta-
tions, including one special lecture and one luncheon lecture.
This Proceedings issue contains one Review Article representing
the special lecture, 8 Original Articles and 5 Letters to the Editor. All
of the papers were peer-reviewed and accepted through the AI re-
view process.
In the Review Article, Prof. Kenji Izuhara and his colleagues
described the history, current understanding and future prospects
of periostin biology in relation to allergic inﬂammation and tissue
ﬁbrosis. I would like to note that serum periostin has two character-
istics as a biomarker for bronchial asthma: it is both a surrogate
biomarker of type 2 immune responses and a biomarker reﬂecting
tissue remodeling and ﬁbrosis.
In one Original Article, Nunomura et al. evaluated the role of
liver X receptors (LXRs) in cytokine production by murine mast
cells. They found that activation of LXRs by a synthetic LXR ligand,
GW3965, attenuated antigen- or lipopolysaccharide (LPS)-induced
production of pro-inﬂammatory cytokines, such as IL-1a and IL-1b,
by the mast cells, and that LXRb played an important role in that
attenuation.
Uchimizu et al. evaluated the concentrations of speciﬁc granular
proteins and the cytokine/chemokine proﬁle in middle ear effusion
samples frompatients with eosinophilic otitis media (EOM) and pa-
tients with secretory otitis media (SOM). They found that the con-
centrations of both eosinophil and neutrophil granular proteins
were signiﬁcantly higher in EOM than in SOM, and that they corre-
lated signiﬁcantly with eosinophil-recruiting chemokine and with
IL-6, respectively. These ﬁndings suggest that not only eosinophils
but also neutrophils are involved in the pathogenesis of middle
ear inﬂammation in EOM.
Ogawa et al. evaluated the role of IL-23 in two distinct antigen-
induced airway inﬂammationmodels (intraperitoneal injection fol-
lowed by intranasal exposure) in IL-23p19-deﬁcient mice. TheyPeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).found that endogenous IL-23 production at the site of OVA sensiti-
zation facilitated type-2 immune responses, whereas house dust
mite (HDM) induced IL-23 production and subsequent IL-17A syn-
thesis in the airways, which in turn suppressed allergic
inﬂammation.
Kobayashi et al. evaluated the effects of stimuli via P2 or P2Y2
receptors on adhesion to ICAM-1, superoxide generation and
eosinophil-derived neurotoxin (EDN) release in eosinophito
ICAM-1, superoxide generation and eosinophil-derived neurotoxin
(EDN) release in eosinophils. As a result, monosodium urate crys-
tals and ATPgS, a non-hydrolysable ATP analog, activated eosino-
phils via P2 or P2Y2 receptors, suggesting that eosinophils may
be directly involved in innate immune responses.
Koyama et al. evaluated the gene expression proﬁles in the lungs
of mice exposed to a crude HDM extract three times intranasally.
They found that, when compared with saline-exposed lungs, genes
related to the Toll-like receptor (TLR) 4 signaling pathway were
markedly induced by day 7, suggesting that this pathway is
involved in sensitization to HDM.
Noguchi et al. evaluated the effects of a long-acting b2 agonist on
eosinophil functions induced by mediators associated with acute
exacerbation, such as cysteinyl leukotrienes (cysLTs) or IP-10.
They found that formoterol, a long-acting b2 agonist, suppressed
adhesion to ICAM-1, production of IL-5 and LTD4, IP-10-induced
O2 generation and EDN release in eosinophils.
Shintani et al. evaluated the mechanisms of how corticosteroid
enhances airway epithelial barrier integrity. Using small interfering
RNAs (siRNAs) for signal transduction molecules, they found that
the nuclear factor erythroid 2-related factor 2 (Nrf2)-aldehyde ox-
idase 1 (AOX1) pathway plays important roles in corticosteroid-
enhanced airway epithelial barrier integrity, and suggested that
this pathway may be a potential therapeutic target for bronchial
asthma.
Kato et al. evaluated the cytokine proﬁles and eosinophil activa-
tion during virus-induced acute asthma exacerbations and found
that serum eosinophil cationic protein (ECP) and IL-5 production
correlated signiﬁcantly with age, whereas serum IP-10 showed an
inverse correlation with age. These results suggest that acute
asthma exacerbations in young children are prone to be related
with viral infection, whereas those in older children are more
type 2 inﬂammation-related.
The 5 Letters to the Editor dealt with cutting-edge topics in both
basic and clinical allergy. The results collectively covered a wide ac-
ademic scope and will signiﬁcantly enhance our insight into thevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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other inﬂammatory cells such asmast cells and basophils, as well as
many cytokines and chemokines.
We sincerely believe that the Workshop and this supplemental
issue will attract signiﬁcant interest from not only the members of
Japanese Society of Allergology but also many other physicians and
researchers around the world. For organizing the Workshop, we
greatly appreciate Prof. Nagata for his excellent management, and
Drs. Soma and Nakagome, and Ms. Aoyama, all of Saitama Medical
University, for devoting much time and effort to the Workshop. We
would also like to thankMs. ToshikoTakeda of the Editorial Ofﬁce of
the Japanese Society of Allergology for her excellent handling of
this supplemental issue.
Personally speaking, I am writing this Editorial while on a ﬂight
back to Tokyo from Chicago, where the 9th Biennial Symposium of
the International Eosinophil Society (IES) was held on July 14e18,
2015 (the ﬁnal program is available at http://www.eosinophil-
society.org/symposia/2015-biennial-symposium/scientiﬁc-
program). Presented at that symposiumwere 4 prenary lectures, 11
special lectures, 15 cutting-edge lectures, 21 oral presentations and
82 poster abstracts dealing with various aspects of eosinophils and
eosinophil-related diseases. More than 200 attendees from over 30
countries held extremely hot discussions that often exceeded the
allotted presentation times!
I would like to introduce a few of the topics discussed at the
symposium. From a historical point of view, eosinophils were ﬁrst
thought to play a favorable role in allergic diseases by degrading
chemical mediators,1 but the situation was completely reversed
in the early 1980s by the ﬁnding that eosinophil-speciﬁc granule
proteins directly damage the bronchial epithelium.2 Even today,
the number of eosinophils in the sputum is the best clinical marker
for optimizing treatment of patients with bronchial asthma.3
Administration of anti-IL-5 monoclonal antibody (mAb) to mild
asthmatic patients strikingly reduced peripheral eosinophil counts,
but it showed no effects on the lung function or late-phase reac-
tions.4 Those ﬁndings dampened eosinophil research. Honestly
speaking, eosinophil researchers, including me, were considered
to be dream-seekers in those days, even though several well-
designed studies revealed the critical roles of eosinophils in the
pathogenesis of airway remodeling and other pathological
conditions.5,6
Recent studies yet again up-ended the general understanding of
the roles of eosinophils. Administration of anti-IL-5 mAb to severe
eosinophil-predominant steroid-refractory asthmatic patients
showed about 50% reduction of asthma exacerbation.7 A subse-
quent study using another clone of anti-IL-5 mAb afﬁrmed that
ﬁnding.8 Thus, I strongly believe that eosinophils are involved inexacerbation in certain types of asthma patients. Of course, further
investigations will be essential to fully elucidate the roles of eosin-
ophils in human diseases. Finally, I found that my personal impres-
sion of current eosinophil biology is perfectly summed up by a
famous quote from Sir Winston Churchill, made on November 10,
1942: “Now this is not the end. It is not even the beginning of the
end. But it is, perhaps, the end of the beginning”.
I ask that you all keep in mind that the 2015 Workshop will be
held on October 24, 2015, in Tokyo under the supervision of Prof.
Koichiro Asano of Tokai University. We hope for even greater
numbers of presentations and attendees on that date. Please check
the website for more details at http://ns1.sec-information.net/
eosinophils/data/announce.html. I am looking forward to seeing
you there.
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